CD8 T-cell Infiltration as a Predictor of Renal Cancer Progression After Surgery
[Technical Report, Annual Report]
EMORY UNIV ATLANTA GA
Pagination or Media Count:
Kidney cancer patients with AJCCTNM Stage III disease represent a significant challenge in selecting the care that should be received after surgery. According to 2019 NCCN guidelines, the decision is whether these patients should either receive sunitinib, enter a clinical trial, or be placed on surveillance. Potentially, this may represent overtreatment or oversurveillance for some patients who are cured, and undertreatment for others. Currently, there are not good indicators to guide which path patients should be follow, thus, appropriate biomarkers are needed to improve prognostication for patients with this stage of disease.
- Medicine and Medical Research
- Anatomy and Physiology